{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-000251","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2022-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.897281+00:00","generated_at":"2026-06-27T04:55:08.770484+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Edgewise reports Q4 2021 net loss $12.7M, cash $281M; EDG-5506 Phase 1b positive","bullets":["Net loss Q4 2021 $12.7M ($0.26/share); full year net loss $42.8M ($1.14/share).","Cash, equivalents & marketable securities $281M as of Dec 31, 2021.","Phase 1b EDG-5506 in BMD: CK reduced 71%, TNNI2 reduced 83%; well-tolerated.","Phase 2 trials planned: BMD in H1 2022, DMD in H2 2022; ARCH open-label study ongoing.","R&D expenses $32.2M in 2021 (vs $15.0M in 2020); G&A $11.0M (vs $2.2M)."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-000251","json":"https://secwatch.observer/filing/0001157523-22-000251.json","markdown":"https://secwatch.observer/filing/0001157523-22-000251.md","text":"https://secwatch.observer/filing/0001157523-22-000251.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000115752322000251/0001157523-22-000251-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000115752322000251/a52584668.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T04:55:08.770484+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}